Anti - Vaccina - CO V ID: Here we go back to normal life

Professor Ugur Sahin today stated that life can return to normality in Great Britain, Europe and the US to next year's “”.

The scientist behind the Pfizer vaccine has told Sky News that people in Great Britain can be vaccinated against the coronary by the middle of next month.

Sahin, co-founder of the German firm BioNTech, said the first vaccines could be distributed to patients across the country in mid-December, but he added it would depend on whether the Great Britain regulator licenses it by that time.

The December “Messis does not mean the situation will change dramatically. This will be a difficult winter. It will get worse before it gets better, he said, adding that people can return to normal life by the middle of next year.

During the interview, Professor Sahin said the efficiency of the 90% vaccine for preventing COVID-19 is an extraordinary “result”.

Professor Sahin said that while the world awaits security checks and government authorisations, the best thing people can do is wear a mask and social distance.

Everybody has a responsibility. It's not just about governments. The most important aspect is to wear a mask, be careful, and avoid many people from being too long in a room,” he said.

BioNtech co-founder Ugur Sahin (55), says he predicted that the cofounder would become a global problem in January.

Asked if he would take the vaccine, he told Sky News: “Yes, of course, I would do the first day I'm allowed. ”

Professor Sahin and his wife Ozlem Turec, 53, are co-founders of the German biotechnology firm working with Pfizer on one of the 12 main tests of anticontour vaccines.

Both of them of Turkish origin met while working in oncology in Germany, establishing their first firm together in 2001. They founded BioNTech in 2008, selling the other company for 1 billion pounds in 2016.

When in January of this year, Professor Sahin faced a scientific paper on a tornado explosion in Wuhan, he noticed how similar his cancer antibodies were to those needed for possible viral vaccines.

B NTech quickly assigned about 500 employees to work on several possible compounds, winning pharmaceutical giant Pfizer and Chinese drug producer Fosun as partners in March